Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixekizumab in radiographic axial spondyloarthritis after prior TNF inhibitor treatment
MOH_2017-03-05_000208Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ixekizumab in ankylosing spondylitis (AS) (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Primary endpoint not reported in provided registry text. Started Feb 2016; status: completed.
02
Drugs
ixekizumab
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on MOH_2017-03-05_000208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-03-05_000208.